OLEMA PHARMACEUTICALS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $652.00K, a 12.83% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $282.00K, a 34.93% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $748.00K, a 15.08% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.03M, a 19.91% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $859.00K, a 18.19% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.05M, a 218.18% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $330.00K, a 54.23% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $652.00K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.03M 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2025-06-30 | $748.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $859.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $650.00K 10-Q · filed 2025-08-11 | |
| 2023-12-31 | $339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.05M 10-K · filed 2025-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $711.00K 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $330.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | |
| 2022-06-30 | $57.00K 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $721.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | |
| 2021-06-30 | $386.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |